Results 11 to 20 of about 3,591 (213)

Evaluating Arrhythmia Risk in Patients with Chronic Obstructive Pulmonary Disease Treated with Aclidinium/Formoterol Fumarate and Other Inhaled Bronchodilators: A Post-Authorization Safety Study [PDF]

International Journal of COPD
Cristina Rebordosa,1 Jaume Aguado,1 Jennifer Bartsch,2 Nuria Saigi-Morgui,1 Anne-Elie Carsin,1 Raquel Garcia-Esteban,1 Elena Ignatova,3 Daniel Freedman,3 Susana Perez-Gutthann,1 Elena Rivero-Ferrer1 1RTI Health Solutions, Barcelona, Spain; 2RTI Health ...
Rebordosa C, Aguado J, Bartsch J, Saigi-Morgui N, Carsin AE, Garcia-Esteban R, Ignatova E, Freedman D, Perez-Gutthann S, Rivero-Ferrer E   +9 more
doaj   +2 more sources

Benefits of budesonide/glycopyrronium/formoterol fumarate dihydrate on lung function and exacerbations of COPD: a post-hoc analysis of the KRONOS study by blood eosinophil level and exacerbation history [PDF]

Respiratory Research
Background Japanese guidelines recommend triple inhaled corticosteroid (ICS)/long-acting muscarinic antagonist (LAMA)/long-acting β2-agonist (LABA) therapy in patients with chronic obstructive pulmonary disease (COPD) and no concurrent asthma diagnosis ...
Shigeo Muro, Tomotaka Kawayama, Hisatoshi Sugiura, Munehiro Seki, Elizabeth A. Duncan, Karin Bowen, Jonathan Marshall, Ayman Megally, Mehul Patel   +8 more
doaj   +2 more sources

Efficacy and safety of fluticasone propionate/formoterol fumarate in pediatric asthma patients: a randomized controlled trial

Therapeutic Advances in Respiratory Disease, 2018
Background: The efficacy and safety of fluticasone propionate/formoterol fumarate pressurized metered-dose inhaler (pMDI) (fluticasone/formoterol; Flutiform ® ; 100/10 µg b.i.d.) was compared with fluticasone propionate (Flixotide ® Evohaler ® pMDI; 100 ...
Anna Płoszczuk, Miroslava Bosheva, Kay Spooner, Tammy McIver, Sanjeeva Dissanayake   +4 more
doaj   +2 more sources

Benefits of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate on COPD Exacerbations, Lung Function, Symptoms, and Quality of Life Across Blood Eosinophil Ranges: A Post-Hoc Analysis of Data from ETHOS [PDF]

International Journal of COPD, 2022
Mona Bafadhel,1 Klaus F Rabe,2 Fernando J Martinez,3 Dave Singh,4 Patrick Darken,5 Martin Jenkins,6 Magnus Aurivillius,7 Mehul Patel,6 Paul Dorinsky8 1Department of Immunobiology, School of Immunology and Microbial Sciences, Faculty of Life Sciences and ...
Bafadhel M, Rabe KF, Martinez FJ, Singh D, Darken P, Jenkins M, Aurivillius M, Patel M, Dorinsky P   +8 more
doaj   +2 more sources

A scintigraphy study of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler in patients with moderate-to-very severe chronic obstructive pulmonary disease [PDF]

Respiratory Research, 2021
Background Triple therapy with inhaled corticosteroids/long-acting muscarinic antagonists/long-acting β2-agonists (ICS/LAMA/LABA) is recommended for patients with chronic obstructive pulmonary disease (COPD) with continued symptoms or exacerbations ...
Omar Usmani, Nicolas Roche, Ezanul Wahab, Samuel Israel, Martin Jenkins, Roopa Trivedi, Paul Dorinsky, Magnus Aurivillius   +7 more
doaj   +2 more sources

Efficacy and safety of two doses of budesonide/formoterol fumarate metered dose inhaler in COPD [PDF]

ERJ Open Research, 2020
Inhaled corticosteroid/long-acting β2-agonist combination therapy is a recommended treatment option for patients with chronic obstructive pulmonary disease (COPD) and increased exacerbation risk, particularly those with elevated blood eosinophil levels ...
Nicola A. Hanania, Alberto Papi, Antonio Anzueto, Fernando J. Martinez, Kimberly A. Rossman, Christy S. Cappelletti, Elizabeth A. Duncan, Jack S. Nyberg, Paul M. Dorinsky   +8 more
doaj   +2 more sources

Efficacy and safety of formoterol fumarate delivered by nebulization to COPD patients [PDF]

Respiratory Medicine, 2008
Nebulized solutions of long-acting bronchodilators provide an alternative to DPI and MDI delivery, particularly for COPD patients unable to use hand-held devices easily or correctly. The long-acting beta2-agonist, formoterol fumarate, is differentiated by its onset of significant bronchodilation within 5 min of administration.
Gross, Nicholas J., Nelson, Harold S., Lapidus, Robert J., Dunn, Leonard, Lynn, Lon, Rinehart, Mike, Denis-Mize, Kimberly   +6 more
openaire   +4 more sources

Beclometasone Dipropionate/Formoterol Fumarate is Similarly Effective to Budesonide/Formoterol Fumarate in Chinese Patients with COPD: The FORSYYN Double-Blind, Randomised Study

COPD
The fixed-dose combination of beclometasone dipropionate/formoterol fumarate (BDP/FF) delivered via pressurised metered-dose inhaler (pMDI) has demonstrated efficacy in chronic obstructive pulmonary disease (COPD), in studies predominantly conducted in ...
Fuqiang Wen, Yanmin Wu, Chunyan Xing, Yingqun Zhu, Yongxing Chen, Xiaodong Mei, Massimo Corradi, Glauco Cappellini, Emanuele Calabro, Sergio Amodio, Cissy Zhu, Dmitry Galkin   +11 more
doaj   +3 more sources

Unique Research for Developing a Full Factorial Design Evaluated Liquid Chromatography Technique for Estimating Budesonide and Formoterol Fumarate Dihydrate in the Presence of Specified and Degradation Impurities in Dry Powder Inhalation. [PDF]

Biomed Chromatogr
ABSTRACT A simple LC method has been developed and validated for estimating budesonide (epimer B + A) and formoterol fumarate dihydrate in dry powder inhalation. The development results of this study make it very significant. The degradation and process impurities in EP and ChP were identified in addition to budesonide and formoterol fumarate.
Bandaru LGR, Konduru N, Kowtharapu LP, Gundla R, Kanuparthy PR, Katari NK.   +5 more
europepmc   +2 more sources

Glycopyrrolate/formoterol fumarate metered dose inhaler for maintenance-naïve patients with chronic obstructive pulmonary disease:a post-hoc analysis of the randomized PINNACLE trials [PDF]

, 2020
Background: Glycopyrrolate (GP)/formoterol fumarate (FF; GFF) metered dose inhaler is a fixed-dose combination dual bronchodilator for patients with chronic obstructive pulmonary disease (COPD); however, whether the efficacy in patients without current ...
A Anzueto, AD D'Urzo, B Alcázar Navarrete, BJ Lipworth, BR Celli, C Tantucci, C Vogelmeier, D Price, D Singh, FJ Martinez, FJ Martinez, GJ Rodrigo, Global Initiative for Chronic Obstructive Lung Disease (GOLD), GT Ferguson, I Naya, J Vestbo, JF Donohue, L Calzetta, L Calzetta, LH Bjermer, M Barrecheguren, M Cazzola, M Decramer, M Decramer, MR Maleki-Yazdi, MT Dransfield, P Rogliani, PO Bridevaux, R Buhl, T Troosters, WP Battisti, Y Oba, YS Punekar   +32 more
core   +2 more sources